Ocular toxoplasmosis in immunocompetent adults: current cost-effectiveness of four treatment regimens in Colombia

Álvarez-García, Valentina; Rubio-Romero, Lorena; Maldonado, María Alejandra; Gómez-Suárez, Marcela; de-la-Torre, Alejandra

doi:10.1016/j.heliyon.2021.e08265

Cited by 4 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were found in an earlier study [32]. It should be noted that T. gondii strains in Latin America have been reported to be more aggressive than the strains in Europe [33]. Furthermore, the results of a European cross-sectional cohort study also showed associations between latent toxoplasmosis and sensory-organ problems.…”

Section: Introductionsupporting

confidence: 87%

Chronic Toxoplasma gondii Infection Modulates Hearing Ability across the Adult Life Span

Getzmann,

Golka,

Bröde

et al. 2024

Life

View full text Add to dashboard Cite

While several studies have shown associations between hearing disorders and congenital toxoplasmosis, the present study investigated the impact of chronic, latent Toxoplasma gondii (T. gondii) infection on hearing loss. We used a regression analysis to explore whether latent T. gondii infection modulates changes in hearing thresholds over an age range from 20 to 70 years. We analyzed audiometric data of 162 T. gondii IgG-positive and 430 T. gondii-negative participants, collected in the Dortmund Vital Study (DVS, ClinicalTrials.gov Identifier: NCT05155397), a prospective study on healthy cognitive aging. The regression analysis indicated that latent toxoplasmosis was associated with an accelerated development in hearing loss over the observed age range. Hearing loss was less frequent in IgG-positive than in IgG-negative participants up to the age of about 40 for a low (0.125–1 kHz)-frequency range. For high (2–8 kHz) frequencies, this pattern reversed for ages above 65 years. We discuss these findings on hearing function in the context of a recently proposed model, suggesting that latent toxoplasmosis can differentially affect brain functions across a lifespan.

show abstract

Section: Introductionsupporting

confidence: 87%

Chronic Toxoplasma gondii Infection Modulates Hearing Ability across the Adult Life Span

Getzmann,

Golka,

Bröde

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

“…However, several factors, such as the high cost, low availability on the market, the large number of tablets, and the potential risk for serious side effects, may lead to the discontinuation of this treatment. Therefore, TMP/SMX treatment has become an attractive option due to its low cost, wide availability, and tolerability (2,17,23). Even though adverse effects like fever, gastrointestinal upset, weight loss, Stevens-Johnson syndrome, toxic epidermal necrolysis, pancreatitis, serum sickness, hyperkalemia, and thrombocytopenia have also been reported (2).…”

Section: Discussionmentioning

confidence: 99%

“…In Colombia, a study investigating the cost-effectiveness of four rst-line treatment regimens found that TMP/SMX had the best performance. This antibiotic treatment has been established as an economical alternative, and its effectiveness is similar to the classic therapy for active toxoplasmic retinochoroiditis (23). Nevertheless, there is no consensus about the best treatment regimens in OT.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of Trimethoprim/ Sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients

Lusambo

Kaimbo

Ngoyi

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Ocular toxoplasmosis (OT) is the leading cause of infectious posterior uveitis in several areas worldwide. The combination of Trimethoprim/Sulfamethoxazole (TMP-SMX) has been presented as an attractive alternative to the “classic’ treatment therapy (Pyrimethamine/Sulfadiazine). Methods A prospective study was carried out between February 2020 and September 2021 in 2 ophthalmic centers in Kinshasa. This study aimed to describe TMP/SMX treatment outcomes for OT in a cohort of immunocompetent Congolese patients. Results 54 patients were included, with a mean age at presentation of 37.5 ± 13.6 years old and a Male-Female ratio of 1.45:1. Three patients (5.6%) presented a recurrence during the follow-up period. At the end of the follow-up, improvement in VA and resolution of inflammation concerned 75.9% and 77.5% of patients, respectively. Cataracts (3.7%), macular scars (3.7%), and vitreous opacities (3.7%) were the principal causes of non-improvement in VA. Treatment-related adverse events were present in 10 patients (18.5%); gastrointestinal (14.8%) and dermatological (3.7%) adverse events were the most frequent. Dermatological adverse events led to discontinuation of treatment. Conclusion TMP/SMX regimen appears to be a safe and effective treatment for OT in Congolese patients. The low cost and the accessibility of the molecules make this regimen an option for treating OT in resource-limited countries.

show abstract

“…However, several factors, such as the high cost, low availability on the market, the large number of tablets, and the potential risk for serious side effects, may lead to the discontinuation of this treatment. Therefore, TMP/SMX treatment has become an attractive option due to its low cost, wide availability, and tolerability [ 2 , 17 , 23 ]. Even though adverse effects like fever, gastrointestinal upset, weight loss, Stevens-Johnson syndrome, toxic epidermal necrolysis, pancreatitis, serum sickness, hyperkalemia, and thrombocytopenia have also been reported [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

“…In Colombia, a study investigating the cost-effectiveness of four first-line treatment regimens found that TMP/SMX had the best performance. This antibiotic treatment has been established as an economical alternative, and its effectiveness is similar to the classic therapy for active toxoplasmic retinochoroiditis [ 23 ]. Nevertheless, there is no consensus about the best treatment regimens in OT.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of trimethoprim/ sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients

Nsiangani Lusambo,

Kaimbo Wa Kaimbo,

Ngoyi Mumba

et al. 2023

BMC Ophthalmol

Self Cite

View full text Add to dashboard Cite

Background Ocular toxoplasmosis (OT) is the leading cause of infectious posterior uveitis in several areas worldwide. The combination of Trimethoprim/Sulfamethoxazole (TMP/SMX) has been presented as an attractive alternative to the “classic’ treatment therapy (Pyrimethamine/Sulfadiazine). Methods A prospective study was carried out between February 2020 and September 2021 in 2 ophthalmic centers in Kinshasa. This study aimed to describe TMP/SMX treatment outcomes for OT in a cohort of immunocompetent Congolese patients. Results 54 patients were included, with a mean age at presentation of 37.5 ± 13.6 years old and a Male-Female ratio of 1.45:1. Three patients (5.6%) presented a recurrence during the follow-up period. At the end of the follow-up, improvement in VA and resolution of inflammation concerned 75.9% and 77.5% of patients, respectively. Cataracts (3.7%), macular scars (3.7%), and vitreous opacities (3.7%) were the principal causes of non-improvement in VA. Treatment-related adverse events were present in 10 patients (18.5%); gastrointestinal (14.8%) and dermatological (3.7%) adverse events were the most frequent. Dermatological adverse events led to discontinuation of treatment. Conclusion TMP/SMX regimen appears to be a safe and effective treatment for OT in Congolese patients. The low cost and the accessibility of the molecules make this regimen an option for treating OT in resource-limited countries.

show abstract

Ocular toxoplasmosis in immunocompetent adults: current cost-effectiveness of four treatment regimens in Colombia

Cited by 4 publications

References 30 publications

Chronic Toxoplasma gondii Infection Modulates Hearing Ability across the Adult Life Span

Chronic Toxoplasma gondii Infection Modulates Hearing Ability across the Adult Life Span

Outcomes of Trimethoprim/ Sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients

Outcomes of trimethoprim/ sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients

Contact Info

Product

Resources

About